Drug Profile
SK 1011
Alternative Names: SK1011Latest Information Update: 17 Jan 2018
Price :
$50
*
At a glance
- Originator Sanwa Kagaku Kenkyusho
- Class Eye disorder therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Choroidal neovascularisation
Most Recent Events
- 17 Jan 2018 No development reported - Phase-II for Choroidal neovascularisation in Japan (PO)